How to access Mepsevii from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with mucopolysaccharidosis type VII (MPS VII, Sly syndrome) — an exceptionally rare inherited lysosomal storage disorder — may receive a prescription for Mepsevii (vestronidase alfa) from their treating metabolic specialist or paediatric geneticist. Mepsevii is FDA-approved in the United States as enzyme-replacement therapy for MPS VII. Because MPS VII is ultra-rare, Mepsevii is almost never stocked locally in India, which is why your specialist will typically coordinate a personal-import pathway for ongoing infusion supply.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Mepsevii is an intravenous enzyme-replacement therapy (recombinant human beta-glucuronidase) administered as an infusion once every two weeks. Eligibility requires biochemical and genetic confirmation of MPS VII. The manufacturer is Ultragenyx. Dosing is typically 4 mg/kg IV every two weeks. The product requires refrigerated storage (2–8 degrees C) and reconstitution before infusion. Monitoring includes urinary GAG levels, pulmonary function, cardiac parameters, skeletal status, infusion-reaction surveillance, and antibody response. Your specialist will confirm MPS VII diagnosis and coordinate the infusion plan.
Is Mepsevii legally importable into India?
Yes — through the personal-import provision recognised under the Drugs and Cosmetics Act and the framework administered by the Central Drugs Standard Control Organization (CDSCO). The framework allows a patient, through their treating physician, to import a quantity of a medicine for personal use when the medicine has been approved by a recognised foreign regulator (FDA qualifies) and is prescribed for their named clinical need. Ultra-rare disease enzyme-replacement therapies are a well-established category of personal-import in India.
The named-patient mechanism rests on four anchors: (a) the medicine is approved by a recognised reference authority such as the FDA, (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the patient. Because Mepsevii is cold-chain, chain-of-custody includes continuous temperature logging.
How the pathway works, step by step
- Consultation with your treating specialist. The decision to prescribe Mepsevii is clinical, based on MPS VII confirmation and baseline organ-system evaluation. Your specialist documents the rationale.
- Infusion-facility identification. A tertiary hospital or infusion centre equipped for bi-weekly enzyme-replacement infusions accepts the case.
- Personal-import documentation. Reserve Meds prepares the personal-import package for customs clearance, including the physician letter, prescription, patient identifier, and chain-of-custody with temperature logging.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Mepsevii travels with validated cold-chain packaging and continuous temperature logging end to end.
- Arrival and infusion. The infusion centre receives the product and administers under your specialist's care. Reserve Meds coordinates the next cycle ahead of depletion.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming MPS VII diagnosis and Mepsevii as the indicated therapy
- Verification of their Indian medical registration (state medical council)
- A current prescription naming the product, dose (mg/kg), and infusion schedule
- Patient identifier (anonymised reference where possible)
- The identified infusion facility and its cold-chain handling capability
Reserve Meds provides a physician documentation kit bundling the templates Indian customs and CDSCO reviewers expect to see for personal-import of cold-chain ultra-rare-disease enzyme-replacement therapies.
Costs and timing
Mepsevii's US cash-pay reference price is weight-dependent and, because MPS VII is ultra-rare, is among the highest-priced enzyme-replacement therapies. A typical paediatric annual cost sits in an indicative 2026 range of roughly USD 500,000–850,000 for ongoing bi-weekly infusions (adult costs scale with weight). Logistics, customs handling, cold-chain shipment, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 21–35 days from the moment a complete dossier is assembled, reflecting the additional coordination typical for ultra-rare-disease products. Subsequent cycles are scheduled to match the bi-weekly infusion calendar.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Mepsevii specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Personal-import documentation package for your physician and for Indian customs handling.
- Logistics. Cold-chain shipment and chain-of-custody coordination with temperature logging.
- Concierge case lead. A named point of contact for your family and your physician throughout the process, sensitive to the exceptional rarity of MPS VII and the complexity of ongoing paediatric care.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating metabolic specialist and the infusion facility. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in India? Yes, when executed through the personal-import provision under the Drugs and Cosmetics Act with appropriate physician documentation. See our trust and compliance page.
What if the cold chain breaks? Our protocol logs temperature continuously; any excursion is assessed against manufacturer stability data. If the product is compromised, we re-source at our cost per service terms.
Are there alternatives to Mepsevii for MPS VII? Mepsevii is the only disease-specific FDA-approved enzyme-replacement therapy for MPS VII. Supportive care and investigational programmes are separate considerations your specialist will discuss.
Will private insurance or patient-assistance programmes cover this? Cash-pay is the default. Some Indian private insurers and manufacturer patient-assistance programmes support named-patient rare-disease imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Mepsevii coordination in India.
Add me to the Mepsevii waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.